RNA interference as an anticancer therapy

A patent perspective

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: The development of RNA interference (RNAi)-based gene silencing approaches has revolutionized biomedical research. These technologies have been applied for functional genomic studies in a variety of areas, including cancer research, by facilitating a better understanding of the mechanisms that underlie tumorigenicity and the identification of novel factors that either promote or inhibit oncogenic transformation. Objective: These approaches have laid the groundwork for the development of a novel class of genetic therapies. Preclinical results have exposed both the unique therapeutic opportunities and challenges that are encountered in adapting these technologies for clinical applications. These themes are reflected in the patent literature that has mirrored the rise in complexity and sophistication of RNAi-based therapeutic approaches. This review focuses on the identification of potential anticancer therapeutic targets and the development of clinically relevant delivery approaches. Conclusions: Thus far, the patent landscape in the RNAi field has been dominated by a handful of key patents that describe the original identification and characterization of inhibitory double-stranded RNA molecules. Only time will tell how these original patents will hold up in the face of the development of new approaches and reagents as RNAi-based therapeutics approach transition from the bench to the clinic.

Original languageEnglish
Pages (from-to)475-491
Number of pages17
JournalExpert Opinion on Therapeutic Patents
Volume19
Issue number4
DOIs
StatePublished - Apr 1 2009

Fingerprint

RNA Interference
Patents
Technology
Literature
Double-Stranded RNA
Gene Silencing
Therapeutics
Genetic Therapy
Biomedical Research
Research
Neoplasms

Keywords

  • Cancer
  • Drug discovery
  • Genetic therapy
  • RNA interference

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

RNA interference as an anticancer therapy : A patent perspective. / Dykxhoorn, Derek M.

In: Expert Opinion on Therapeutic Patents, Vol. 19, No. 4, 01.04.2009, p. 475-491.

Research output: Contribution to journalArticle

@article{c07ef84fdae544e1a38ea85daab017f2,
title = "RNA interference as an anticancer therapy: A patent perspective",
abstract = "Background: The development of RNA interference (RNAi)-based gene silencing approaches has revolutionized biomedical research. These technologies have been applied for functional genomic studies in a variety of areas, including cancer research, by facilitating a better understanding of the mechanisms that underlie tumorigenicity and the identification of novel factors that either promote or inhibit oncogenic transformation. Objective: These approaches have laid the groundwork for the development of a novel class of genetic therapies. Preclinical results have exposed both the unique therapeutic opportunities and challenges that are encountered in adapting these technologies for clinical applications. These themes are reflected in the patent literature that has mirrored the rise in complexity and sophistication of RNAi-based therapeutic approaches. This review focuses on the identification of potential anticancer therapeutic targets and the development of clinically relevant delivery approaches. Conclusions: Thus far, the patent landscape in the RNAi field has been dominated by a handful of key patents that describe the original identification and characterization of inhibitory double-stranded RNA molecules. Only time will tell how these original patents will hold up in the face of the development of new approaches and reagents as RNAi-based therapeutics approach transition from the bench to the clinic.",
keywords = "Cancer, Drug discovery, Genetic therapy, RNA interference",
author = "Dykxhoorn, {Derek M}",
year = "2009",
month = "4",
day = "1",
doi = "10.1517/13543770902838008",
language = "English",
volume = "19",
pages = "475--491",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - RNA interference as an anticancer therapy

T2 - A patent perspective

AU - Dykxhoorn, Derek M

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Background: The development of RNA interference (RNAi)-based gene silencing approaches has revolutionized biomedical research. These technologies have been applied for functional genomic studies in a variety of areas, including cancer research, by facilitating a better understanding of the mechanisms that underlie tumorigenicity and the identification of novel factors that either promote or inhibit oncogenic transformation. Objective: These approaches have laid the groundwork for the development of a novel class of genetic therapies. Preclinical results have exposed both the unique therapeutic opportunities and challenges that are encountered in adapting these technologies for clinical applications. These themes are reflected in the patent literature that has mirrored the rise in complexity and sophistication of RNAi-based therapeutic approaches. This review focuses on the identification of potential anticancer therapeutic targets and the development of clinically relevant delivery approaches. Conclusions: Thus far, the patent landscape in the RNAi field has been dominated by a handful of key patents that describe the original identification and characterization of inhibitory double-stranded RNA molecules. Only time will tell how these original patents will hold up in the face of the development of new approaches and reagents as RNAi-based therapeutics approach transition from the bench to the clinic.

AB - Background: The development of RNA interference (RNAi)-based gene silencing approaches has revolutionized biomedical research. These technologies have been applied for functional genomic studies in a variety of areas, including cancer research, by facilitating a better understanding of the mechanisms that underlie tumorigenicity and the identification of novel factors that either promote or inhibit oncogenic transformation. Objective: These approaches have laid the groundwork for the development of a novel class of genetic therapies. Preclinical results have exposed both the unique therapeutic opportunities and challenges that are encountered in adapting these technologies for clinical applications. These themes are reflected in the patent literature that has mirrored the rise in complexity and sophistication of RNAi-based therapeutic approaches. This review focuses on the identification of potential anticancer therapeutic targets and the development of clinically relevant delivery approaches. Conclusions: Thus far, the patent landscape in the RNAi field has been dominated by a handful of key patents that describe the original identification and characterization of inhibitory double-stranded RNA molecules. Only time will tell how these original patents will hold up in the face of the development of new approaches and reagents as RNAi-based therapeutics approach transition from the bench to the clinic.

KW - Cancer

KW - Drug discovery

KW - Genetic therapy

KW - RNA interference

UR - http://www.scopus.com/inward/record.url?scp=67649624970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649624970&partnerID=8YFLogxK

U2 - 10.1517/13543770902838008

DO - 10.1517/13543770902838008

M3 - Article

VL - 19

SP - 475

EP - 491

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 4

ER -